Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety, tolerability, and immunogenicity of EGFR(V)-EDV-Dox in subjects with recurrent glioblastoma and Grade IV astrocytoma has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Grade Iv
• Glioblastoma

Drugs mentioned

• EGFR(V)-EDV-Dox

Snippet

Sponsor: Engeneic Pty Limited | Conditions: Glioblastoma, Astrocytoma, Grade IV | Phase 1 | Status: COMPLETED